Cargando…
GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy
Lipid nanoparticles have demonstrated utility in hepatic delivery of a range of therapeutic modalities and typically deliver their cargo via low-density lipoprotein receptor-mediated endocytosis. For patients lacking sufficient low-density lipoprotein receptor activity, such as those with homozygous...
Autores principales: | Kasiewicz, Lisa N., Biswas, Souvik, Beach, Aaron, Ren, Huilan, Dutta, Chaitali, Mazzola, Anne Marie, Rohde, Ellen, Chadwick, Alexandra, Cheng, Christopher, Garcia, Sara P., Iyer, Sowmya, Matsumoto, Yuri, Khera, Amit V., Musunuru, Kiran, Kathiresan, Sekar, Malyala, Padma, Rajeev, Kallanthottathil G., Bellinger, Andrew M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185539/ https://www.ncbi.nlm.nih.gov/pubmed/37188660 http://dx.doi.org/10.1038/s41467-023-37465-1 |
Ejemplares similares
-
Overexpression of GalNAc-transferase GalNAc-T3 Promotes Pancreatic Cancer Cell Growth
por: Taniuchi, Keisuke, et al.
Publicado: (2011) -
Expression of alpha-GalNAc glycoproteins by breast cancers.
por: Brooks, S. A., et al.
Publicado: (1995) -
The GalNAc-T Activation (GALA) Pathway: Drivers and markers
por: Chia, Joanne, et al.
Publicado: (2019) -
The Gal/GalNac lectin as a possible acetylcholine receptor in Entamoeba histolytica
por: Pacheco-Sánchez, Marisol, et al.
Publicado: (2023) -
Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates
por: Nair, Jayaprakash K., et al.
Publicado: (2017)